Response to Comments: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

This document is a response-to-comments article for the Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) LCD L40052 and does not itself specify clinical coverage indications, limitations, documentation requirements, or frequency limits. It records the LCD comment period (2/7/25–3/23/25) and notes the LCD notice start date (9/11/25) and effective date (10/26/25); refer to LCD L40052 for the actual coverage criteria.

"This article is a 'response to comments' for LCD L40052 (Allergen Immunotherapy with SCIT) and does not itself state clinical coverage criteria; it references the LCD notice period beginning 2025-0..."

Sign up to see full coverage criteria, indications, and limitations.